Little Pharma shares lift 8% amid appointment of ‘highly regarded’ director

Little Green Pharma shares are smoking the market today.

| More on:
little green pharma share price represented by cannabis leaf character jumping cheerfully

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Little Green Pharma shares surge 8.33% to 32.5 cents during early afternoon trade 
  • The company announced the inclusion of Beatriz Vicén Banzo on its board 
  • The appointment will see Banzo serve as a non-executive director effective immediately 

The Little Green Pharma Ltd (ASX: LGP) share price is flying on Thursday following a company update.

At the time of writing, the medicinal cannabis’ shares are up 8.33% to 32.5 cents.

What did Little Green Pharma announce?

In the morning, Little Green Pharma provided investors with a board appointment which has led its shares to push higher.

According to its release, the company announced the inclusion of experienced pharmaceutical regulatory executive, Beatriz Vicén Banzo on its board.

Serving as a non-executive director effective today, Banzo brings a wealth of experience to the role. Her decorated career spans large multinational companies with a focus on regulatory affairs for European pharmaceutical enterprises.

Banzo sat on the board as director of public affairs and quality for global pharmaceutical leader, Bayer in Spain.

In her position, Banzo was responsible for a number of important business functions. This included quality assurance, regulatory affairs, pricing and market access across the business’s divisions.

Prior to this, Banzo held the title of head of regulatory affairs and permanent executive committee guest at Novartis Pharmaceutical for almost 10 years.

Banzo has a degree in pharmacy as well as an MBA from the University of Barcelona.

She also possesses a masters in European regulatory procedures as well as an additional MBA from ESADE business school.

Notably, the appointment coincides with Little Green Pharma’s expansion of its operations throughout Europe.

The Spanish market represents an emerging opportunity for the company given the country’s large population of 50 million people.

Little Green Pharma is seeking a stronger foothold in the European market as interest increases in the cannabis medicines industry.

Management commentary

Little Green Pharma CEO, Fleta Solomon said:

I am very excited to welcome Beatriz to the leadership team at Little Green Pharma. Her experience in international pharmaceutical management and regulation is unmatched and will no doubt be a major asset to the Company as we continue to expand.

In particular, she has detailed knowledge of the development requirements for products in European and international markets, as well as experience executing strategies to build leadership positions in the pharmaceutical industry, highlighted by her time at multinational company Bayer.

Little Green Pharma share price snapshot

Over the last 12 months, Little Green Pharma shares have tumbled by more than 62%.

The company’s share price reached a multi-year low of 21.5 cents last month, before recovering some lost ground.

Based on today’s price, Little Green Pharma has a market capitalisation of around $72.08 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cannabis Shares

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they’re at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here’s why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »

little green pharma share price represented by cannabis leaf character jumping cheerfully
Cannabis Shares

Little Green Pharma share price shoots 13% higher after capital raise

There's considerable excitement in the medicinal cannabis space as Australia becomes the world's first market to recognise psychedelics as medicines.

Read more »

An older farmer wearing a checkered shirt and a straw hat stands in a green field of cannabis plants growing up to waist level as he smiles while thinking about the outlook for ASX cannabis shares in FY23
Cannabis Shares

Buying ASX cannabis stocks? Here’s what the Victorian government is considering right now

Victoria became the first state to legalise medicinal cannabis in 2016. Now the government is playing catch-up with other laws.

Read more »

A graphic showing a rising share price in medical cannabis shares
Cannabis Shares

Why did this ASX 300 cannabis share just rocket 12%?

Incannex is going to make its own pharmaceutical-grade psilocybin drug for clinical trials and potential commercial use.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Why did this ASX cannabis share just rocket 46%?

This cannabis share has been given a major boost by regulators...

Read more »